Descriptive study assesses levonadifloxacin's impact on gram-positive and gram-negative isolates in ICU, indicating potential clinical utility.
Key Points
Levonadifloxacin showed excellent in vitro activity against gram-positive cocci, including multidrug-resistant strains.
Among 135 isolates, 76.29% were resistant to levofloxacin, highlighting significant resistance among gram-negative bacilli.
Using broth microdilution, minimum inhibitory concentrations for levonadifloxacin were determined as per CLSI guidelines.
Despite its effectiveness against gram-positive bacteria, levonadifloxacin's limited efficacy against gram-negative bacilli calls for further research.